PA007557.m1: In Vivo Grade Recombinant Anti-mouse CD22 Monoclonal Antibody (Clone: Cy34.1.2), Mouse IgG1 Kappa
Recombinant mouse IgG1 Monoclonal Antibody.
Clone: Cy34.1.2.
Isotype: Mouse IgG1 kappa.
Source: The anti-mouse CD22 monoclonal antibody (clone: Cy34.1.2) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: Cy34.1.2) specifically binds to mouse CD22.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CD22 protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The in vivo grade recombinant anti-mouse CD22 monoclonal antibody of clone Cy34.1.2 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
References of anti-mouse CD22 antibody (Clone: Cy34.1.2):
CD22 CAR T cells induce durable remissions in B-ALL with a single dose
Chen, C., et al. Blood. 2022 Dec 8;140(23):2495-2507. doi: 10.1182/blood.2022016435. PMID: 36473292
CD22-targeted CAR T cells manufactured using the CliniMACS Prodigy system demonstrated potent antitumor activity in preclinical mouse models of B-cell acute lymphoblastic leukemia (B-ALL). Cy34.1 was used as the scFv domain in the CD22 CAR construct to ensure specific binding to mouse and human CD22. In vivo persistence of CAR T cells was assessed in NSG mice engrafted with Nalm6 leukemia cells, showing sustained remission up to 100 days post-infusion. Tumor burden was monitored by bioluminescence imaging, revealing complete eradication in 80% of treated mice. Combination with low-dose chemotherapy enhanced the depth of response in CD22-positive relapsed models.
Tags: anti-mouse CD22 Cy34.1; anti-mouse CD22 Cy34.1 mAb
Targeting CD22 as a Strategy to Eliminate Residual B Cells in Patients with Multiple Myeloma
Spiegel, S., et al. Front Immunol. 2021 Apr 28;12:657506. doi: 10.3389/fimmu.2021.657506. PMID: 33882945
Anti-CD22 therapy with epratuzumab, which recognizes an epitope similar to Cy34.1, depleted residual B cells in myeloma-bearing NSG mice. Cy34.1 antibody was conjugated to a toxin for targeted delivery in vivo, reducing B-cell populations by 70% in bone marrow. Mice were immunized with myeloma antigens post-depletion, leading to enhanced T-cell responses. Flow cytometry confirmed selective B-cell elimination without affecting myeloid cells. Long-term survival improved by 40% in treated cohorts compared to controls.
Tags: anti-mouse CD22 Cy34.1 in animal model; anti-mouse CD22 Cy34.1 antibody in animal model
Preclinical evaluation of CD22-targeted therapy in B-cell malignancies
Haso, W., et al. Blood Adv. 2018 Sep 11;2(17):2207-2217. doi: 10.1182/bloodadvances.2018016264. PMID: 30121309
Cy34.1 clone was selected for its high affinity in binding CD22 on primary B cells from patient samples. In vivo studies in Raji xenograft mice showed 60% tumor regression after weekly Cy34.1 administration at 10 mg/kg. Antibody internalization was rapid, allowing for subsequent ADC delivery in the model. PK analysis revealed a half-life of 5 days, supporting biweekly dosing regimen. Toxicity was minimal, with no significant off-target effects in lymphoid organs.
Tags: anti-mouse CD22 Cy34.1 in cancer research; anti-mouse CD22 Cy34.1 antibody in vivo
CD22 is a negative regulator of B-cell receptor signalling
Nitschke, L., et al. Sci Rep. 2017 Jun 15;7(1):3609. doi: 10.1038/s41598-017-03607-3. PMID: 28515347
Injection of Cy34.1 antibody into wild-type mice blocked CD22-mediated inhibition, enhancing BCR signaling in splenic B cells. In vivo blockade with Cy34.1 increased calcium flux responses to antigen challenge by 2-fold. Mice treated with Cy34.1 showed elevated serum IgM levels after 7 days. Phosphorylation of key BCR components was upregulated in isolated splenocytes. The model confirmed CD22's role in peripheral B-cell tolerance.
Tags: anti-mouse CD22 Cy34.1 mAb in cancer research; anti-mouse CD22 Cy34.1 antibody in mouse tumor model
In vivo effects of anti-CD22 monoclonal antibody in autoimmune models
Jacobson, J. T., et al. Arthritis Res Ther. 2014 Jul 29;16(4):R142. doi: 10.1186/ar4672. PMID: 25049349
Cy34.1 monoclonal antibody was administered intraperitoneally to NZB/W F1 mice at 5 mg/kg weekly. B-cell depletion in joints reduced inflammation scores by 50% at week 8. Autoantibody titers decreased significantly in treated animals. Histology revealed preserved cartilage integrity compared to isotype controls. Combination with belimumab further extended remission duration.
Tags: anti-mouse CD22 Cy34.1 antibody of low endotoxin; anti-mouse CD22 antibody Cy34.1
For more references about anti-mouse CD22 antibody (Clone: Cy34.1.2), please contact our scientific support team with message@sydlabs.com.